Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed), eta | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Leishmania major | DNA polymerase eta, putative | 0.0054 | 0.9701 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.1847 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.1847 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.1847 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Schistosoma mansoni | DNA polymerase eta | 0.0054 | 0.9701 | 0.9633 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0054 | 0.9701 | 0.9633 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0054 | 0.9701 | 1 |
Leishmania major | DNA polymerase eta, putative | 0.0038 | 0.5597 | 0.4775 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Echinococcus multilocularis | dna polymerase eta | 0.0054 | 0.9701 | 0.9633 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0038 | 0.5597 | 0.4775 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.1847 | 0.1904 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1847 | 0.5 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.1847 | 0.5 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Loa Loa (eye worm) | hypothetical protein | 0.0054 | 0.9701 | 0.9633 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0054 | 0.9701 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Echinococcus granulosus | dna polymerase eta | 0.0054 | 0.9701 | 0.9633 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0038 | 0.5597 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0033 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.